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Abstract
Introduction: Delirium occurs frequently in critically ill patients and is associated with disease severity and
infection. Although several pathways for delirium have been described, biomarkers associated with delirium in
intensive care unit (ICU) patients is not well studied. We examined plasma biomarkers in delirious and nondelirious
patients and the role of these biomarkers on long-term cognitive function.
Methods: In an exploratory observational study, we included 100 ICU patients with or without delirium and with
("inflamed”) and without ("noninflamed”) infection/systemic inflammatory response syndrome (SIRS). Delirium was
diagnosed by using the confusion-assessment method-ICU (CAM-ICU). Within 24 hours after the onset of delirium,
blood was obtained for biomarker analysis. No differences in patient characteristics were found between delirious
and nondelirious patients. To determine associations between biomarkers and delirium, univariate and multivariate
logistic regression analyses were performed. Eighteen months after ICU discharge, a cognitive-failure questionnaire
was distributed to the ICU survivors.
Results: In total, 50 delirious and 50 nondelirious patients were included. We found that IL-8, MCP-1, procalcitonin
(PCT), cortisol, and S100-b were significantly associated with delirium in inflamed patients (n = 46). In the
noninflamed group of patients (n = 54), IL-8, IL-1ra, IL-10 ratio Ab1-42/40, and ratio AbN-42/40 were significantly
associated with delirium. In multivariate regression analysis, IL-8 was independently associated (odds ratio, 9.0; 95%
confidence interval (CI), 1.8 to 44.0) with delirium in inflamed patients and IL-10 (OR 2.6; 95% CI 1.1 to 5.9), and
Ab1-42/40 (OR, 0.03; 95% CI, 0.002 to 0.50) with delirium in noninflamed patients. Furthermore, levels of several
amyloid-b forms, but not human Tau or S100-b, were significantly correlated with self-reported cognitive
impairment 18 months after ICU discharge, whereas inflammatory markers were not correlated to impaired long-
term cognitive function.
Conclusions: In inflamed patients, the proinflammatory cytokine IL-8 was associated with delirium, whereas in
noninflamed patients, antiinflammatory cytokine IL-10 and Ab1-42/40 were associated with delirium. This suggests that
the underlying mechanism governing the development of delirium in inflamed patients differs from that in
noninflamed patients. Finally, elevated levels of amyloid-b correlated with long-term subjective cognitive-impairment
delirium may represent the first sign of a (subclinical) dementia process. Future studies must confirm these results.
The study was registered in the Clinical Trial Register (NCT00604773).
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Introduction
Delirium is a serious and frequently occurring disorder
in critically ill patients associated with both physical and
cognitive impaired outcome [1-4]. Because the patho-
genesis of delirium is probably multifactorial, biomarker
analysis may provide valuable information regarding the
underlying mechanisms [5-7].
Several previous investigations in non-ICU patients
established an association between inflammation and
delirium, as correlations between proinflammatory
cytokine levels and delirium have been found [6,8-10].
Furthermore, in elderly delirious patients with hip
fractures, increased concentrations of IL-6, IL-8, and
cortisol were correlated with elevated levels of the
brain-specific protein (BSP) S100-b (a marker for
astrocyte damage) [11]. Interestingly, sepsis is also
associated with elevated levels of BSP [12,13]. Further-
more, it has been hypothesized that serious illness
such as sepsis, as well as the use of sedatives and
analgesic, could result in apoptosis and long-term cog-
nitive impairment [14]. In mice, tumor-necrosis factor
(TNF)-a is a mediator of apoptotic cellular death in
the brain [15] and may therefore be causally asso-
ciated with the development of delirium in patients
with severe inflammation.
In the long term, delirium is associated with a more
than 12-fold increased risk for developing dementia
[16], resulting in permanent impairment of cognitive
function that is associated with altered levels of amy-
loid-b [17,18]. The association between biomarkers in
delirious patients and long-term cognitive function is
unknown.
With regard to its multifactorial nature, it is likely that
the underlying mechanisms of delirium may differ
between inflamed and noninflamed patients. In the pre-
sent study, we explored which biomarkers were asso-
ciated with delirium in inflamed patients and which
were associated with delirium in noninflamed patients,
thereby using these biomarkers to explore whether dif-
ferent underlying mechanisms are involved. We
included biomarkers that are directly linked to delirium,
as determined in previous studies, and biomarkers that
are linked with the onset of delirium. Apart from well-
established pro- and antiinflammatory cytokines, we
determined, for example, procalcitonin [19], macrophage
migration inhibitory factor [20], and human neutrophil
peptide-1 [21], which play a role in inflammation,
directly associated with delirium [22]. Finally, we
searched for correlations between mediators that were
related to delirium and brain-specific proteins and cog-
nitive functions 18 months after ICU discharge to estab-
lish whether the different pathways exert different long-
term cognitive effects.
Material and methods
Patients and definitions
A convenience sample was taken of all medical and sur-
gical patients older than 18 years admitted to our Inten-
sive Care Department (tertiary referral hospital in
Nijmegen, the Netherlands) between February and July
2008. These patients were screened for delirium by
using the confusion-assessment method-ICU (CAM-
ICU) [23,24]. Patients were excluded when delirium
screening during patients’ complete ICU stay could not
be performed (for example, because of persistent coma).
Patients who were admitted to the ICU for trauma,
postcardiac arrest, or neurologic reasons were also
excluded. Finally, patients were excluded when they had
a history of serious cognitive impairment, defined as
reported in their medical history, or had from any form
of dementia, delirium, or obvious signs of cognitive
impairment reported by their relatives. If doubt existed
concerning preexistent cognitive function, patients were
not included in this study.
In delirious patients, blood was drawn within 24 hours
after the onset of delirium. For the nondelirious group,
because no point in time exists to relate to, we draw
blood after a similar ICU length of stay compared with
that of the group of delirious patients. A total of 5 ml
blood was drawn for all measurements.
Delirium and nondelirium patients were furthermore
divided into inflamed and noninflamed patients. This dis-
tinction was made because inflamed patients are suspected
to have high levels of inflammatory mediators, and from a
group of noninflamed patients, it is expected that they
have low levels of inflammatory mediators. Inflamed was
defined as a positive culture, regardless the origin from
which specimens were taken, for which the patient was
treated with antibiotics. Although systemic inflammatory
response syndrome (SIRS) criteria lack specificity, the
study was designed to differentiate between inflamed
patients and noninflamed patients, and therefore, we used
the presence of more than two SIRS criteria as a marker of
inflammation [25]. Absence of inflammation was defined
as the absence of proven or suspected infection and the
presence of no more than one SIRS criterion.
The regional Medical Ethics Committee of Arnhem-
Nijmegen approved the study and waived the need for
informed consent because a single blood withdrawal is
not considered a burden for the patient, and the results
of this study did not influence the standard care for that
patient. The study was registered in the Clinical Trial
Register (NCT00604773).
Procedures
Demographic variables as well as illness-related charac-
teristics were collected. The validated CAM-ICU
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method was used to detect whether patients were
delirious. All patients were screened at least 3 times
per day by using the CAM-ICU, with a high interrater
reliability of 0.90 (95% CI, 0.82 to 0.98) Cohen kappa
by well-trained ICU nurses [26]. Patients were diag-
nosed with delirium when they had at least one posi-
tive CAM-ICU screening. Patients without any positive
CAM-ICU screening during the complete ICU stay
were classified as nondelirious. In case of doubt
regarding the delirium diagnosis, patients were not
included in this study.
Blood for the determination of biomarkers was drawn
between 6 and 10 a.m. and within 24 hours of the first
positive CAM-ICU screening from an indwelling arterial
line. Blood was centrifuged at 2,000 g for 15 minutes,
and plasma was stored at -80°C until analysis. Proin-
flammatory cytokines (tumor necrosis factor (TNF)-a,
interleukin (IL)-1b, IL-6, IL-8, IL-17, IL-18, and macro-
phage migration inhibitory factor (MIF), antiinflamma-
tory cytokines (IL-1RA and IL-10), and the chemotactic
cytokine MCP-1 were determined by using a simulta-
neous Luminex assay (Milliplex; Millipore, Billerica,
MA, USA). Plasma defensin (human neutrophil peptide-
1 (HNP-1)) was measured by using mouse anti-human
HNP-1-3 monoclonal antibody (HyCult Biotechnology,
Uden, The Netherlands), and the wells were then incu-
bated with rabbit anti-human HNP-1-3 polyclonal anti-
body (Host Defence Research Centre, Toronto, ON,
Canada), followed by incubation with peroxidase-conju-
gated goat-anti-rabbit IgG (Jackson ImmunoResearch).
C-reactive protein (CRP) concentrations were measured
by using immunologic detection (turbidimetric method,
Aeroset; Abbott Laboratories, Abbott Park, IL, USA),
and procalcitonin (PCT) levels were determined by
using an immunometric assay with time-resolved ampli-
fied cryptate emission technology (PCT-sensitive Kryp-
tor kit; Brahms, Middletown, VA, USA). The stress
hormone cortisol was measured with luminometric
immunoassay on a random-access analyzer (Architect i
System, Abbott).
The brain-specific proteins full-length amyloidb1-42
and 1-40 (Ab1-42 and Ab1-40) and truncated Ab-42 and
-40 (AbN-42 and AbN-40) were determined in plasma by
using a simultaneous Luminex assay (INNO-BIA plasma
Ab forms; Innogenetics, Ghent, Belgium), which has
been shown to be a reliable assay with a low variability
[27]. Plasma levels of S100 calcium-binding protein-b
(S100-b) and total human Tau were analyzed by using
two commercially available enzyme-linked immunosor-
bent assay (ELISA) kits (Cosmo Bio Co., Ltd., Tokyo,
Japan; and Cusabio Biotech Co. Ltd., Donghu; China,
respectively). All biomarkers were determined according
to the manufacturer’s instructions.
Subjective long-term cognitive functioning
All included patients received the validated Dutch trans-
lation [28] of the cognitive-failure questionnaire (CFQ)
18 months (median) after discharge from the ICU [29].
The self reported CFQ measures four dimensions of
cognition: memory, distractibility, social blunders, and
names [30]. Each question was scored on a 5-point
Likert scale. The total score on the CFQ ranges from 0
to 100; a higher score indicates more-severe cognitive
dysfunctioning. The subjective CFQ shows good correla-
tion with more-quantitative mental health tests [29]. An
extensive description concerning the use of the CFQ in
critically ill patients was recently published [31].
Statistical analysis
Differences in baseline characteristics between delirious
and nondelirious patients were tested by using c2 tests
and the Mann-Whitney U or Student t tests, depending
on its measure and distribution. Biomarkers and CFQ
data were successfully log transformed to obtain nor-
mally distributed data. To determine the association
between biomarkers and delirium in the inflamed and
the noninflamed group of patients, univariate logistic
regression analysis was performed. To examine the asso-
ciations between the biomarkers and delirium, a multi-
variate logistic regression analysis method backward
conditional was performed, including biomarkers with
the 10 best-associated biomarkers in the univariate ana-
lysis. Correlations between biomarkers and CFQ out-
comes, measured 18 months after ICU discharge, were
determined by using Pearson’s correlation coefficients.
Because of the exploratory nature of this study, no
correction for multiple testing was performed to
increase sensitivity. Statistical significance was defined as
a P value < 0.05.
All data were analyzed by using SPSS version 16.01
(SPSS, Chicago, IL, USA).
Results
In total, 105 patients were screened for this study, of
which five patients were excluded for reasons of doubt
concerning the delirium diagnosis or history of cognitive
dysfunction of the patients. In three patients, it was not
possible to retrieve information about the relatives, and
in two patients, some doubt existed concerning the delir-
ium diagnosis (in both cases, the CAM-ICU was nega-
tive). In total, 100 patients were included for this study,
of whom 50 patients were delirious during the ICU stay,
and 50 patients were not delirious during the ICU stay.
No statistically significant differences in demographic
variables and several clinical covariates related to delir-
ium were observed between groups of 50 delirious and
50 nondelirious patients (Table 1). No difference was
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noted between both groups regarding the moment of
blood withdrawal counted from ICU admission (Table 1).
Several pro- and antiinflammatory cytokines, PCT as
marker of inflammation, stress response hormone corti-
sol, as well as several brain-specific proteins differed sig-
nificantly between delirious and nondelirious patients
(Table 2). Of note, all measured levels of biomarkers
were well above the lower detection limit. Differences in
biomarkers between inflamed and noninflamed delirious
patients are illustrated in Additional file 1.
Inflamed patients
This group consisted of 26 delirium and 20 nondelir-
ium ICU patients. Several pro- as well as antiinflam-
matory cytokines, PCT, and cortisol were significantly
higher in the delirium group compared with the non-
delirium group (Table 3). Levels of brain-specific pro-
teins were comparable between the groups, except for
a borderline-significant elevated level of S100-b in the
delirium group (P = 0.07). In univariate logistic regres-
sion analysis, IL-8, MCP-1, PCT, cortisol, and S100-b
were significantly (P <0.05) associated with delirium.
Extended with the biomarkers TNF-a, IL-6, IL-18, IL-
1ra, and IL-10, the 10 best biomarkers associated with
delirium (all P < 0.10) were then entered into a multi-
variate logistic regression analysis. This multivariate
analysis demonstrated a significant association between
the proinflammatory cytokine IL-8 (odds ratio, 9.0;
95% CI, 1.8 to 44.0) with the presence of delirium in
inflamed patients.
Noninflamed patients
This group of patients consisted of 24 delirium and 30
nondelirium ICU patients. The proinflammatory cyto-
kines IL-6 and IL8 as well as the antiinflammatory
cytokines IL-1ra and IL-10 and level of PCT were
significantly higher in delirious patients compared with
the nondelirious patients. Furthermore, several amy-
loid-b forms differed significantly, and Tau levels dif-
fered borderline significantly between the two groups
(Table 3).
Biomarkers that were significantly associated with
delirium were IL-8, IL-1ra, IL-10, ratio Ab1-42/40, and
ratio AbN-42/40. Furthermore IL-6, PCT, cortisol, ratio
Tau/Ab1-42, Ab1-40, and AbN-40 were in total the 10
best, with delirium-associated biomarkers (all P < 0.10)
in univariate logistic regression analysis. Multivariate
logistic regression analyses with these biomarkers
showed a significant association of ratio Ab-42/40 (OR,
0.03; 95% CI, 0.002 to 0.50) and the antiinflammatory
cytokine IL-10 (OR, 2.6; 95% CI, 1.1 to 5.9) with the
presence of delirium in noninflamed patients.
Correlations of biomarkers with long-term subjective
cognitive failure
At a median of 18 months after ICU discharge, 10 of
the 100 ICU patients had died. Except for a significantly
lower level of IL-1b in the survivors group, no other dif-
ferences were found between the survivors and nonsur-
vivors (data not shown).
In total, 52 (58%) patients of the 90 survivors returned
the CFQ; 23 (44%) of these were delirious during their
ICU stay. No important differences were noted between
nonresponders and responders concerning age (69 ± 8
versus 73 ± 6 years; P = 0.12), APACHE-II (16 ± 3 ver-
sus 15 ± 4; P = 0.31), gender (male, 46%, versus 54%; P
= 0.45), delirium (46% versus 44%; P = 0.60), and
inflamed (55% versus 40%; P = 0.29).
The Ab1-40 and the Ab1-42/40 ratio correlated with the
domain distractibility (r = 0.30; P = 0.03; and r = -0.28;
P = 0.04, respectively). The AbN-42/40 ratio correlated
with the domain memory (r = -0.30; P = 0.03). AbN-40
Table 1 Demographic variables of delirium and nondelirium ICU patients
Delirium
(n = 50)
Nondelirium
(n = 50)
P value
Age in years (95% CI) 72 (38-86) 68 (31-84) 0.10
Gender (male, n, %) 27 (46) 26 (40) 0.50
Medical patients (n, %) 14 (28) 13 (26) 0.50
Unplanned admissions (n, %) 23 (46) 7 (35) 0.34
APACHE-II score (point)
(95% CI)
16 (9-25) 15 (6-23) 0.11
Inflamed patients (n, %) 26 (52) 20 (40) 0.16
Days on the ICU (median [IQR] before blood drawn 1 [1,2] 1 [1-3] 0.38
Mean arterial blood pressure in mm Hg (95% CI) 64 (47-90) 65 (50-105) 0.37
Use of sedatives (midazolam, propofol) (n, %) 28 (56) 16 (32) 0.13
Use of opiates (n, %) 45 (90) 42 (84) 0.28
Urea in mmol/L (95% CI) 11 (4-29) 9 (4-23) 0.14
Metabolic acidosis (n, %) 15 (30) 14 (28) 0.50
Data are expressed as mean and standard deviation (±), unless other reported.
van den Boogaard et al. Critical Care 2011, 15:R297
http://ccforum.com/content/15/6/R297
Page 4 of 9
correlated with the domain social blunders (r = 0.31; P
= 0.03). AbN-40 and the AbN-42/40 ratio correlated signifi-
cantly with the total CFQ score (r = 0.30; P = 0.04; and
r = -0.34; P = 0.02, respectively).
We found no correlation between S100-b, total human
Tau, cortisol, or any of the other measured inflamma-
tory mediators, CFQ, age, APACHE-II score, and mean
blood pressure. In addition, we found no correlations
between CFQ and age, APACHE-II score, and length of
stay in the ICU.
The patient numbers per subgroup were too low and
therefore did not allow us to perform correlation ana-
lyses between biomarkers and the different subgroups
because of lack of statistical power.
Discussion
This study shows that differences exist in various
inflammatory mediators associated with delirium
between inflamed and noninflamed patients. After mul-
tivariate regression analysis, IL-8 was associated with
delirium in inflamed patients, whereas in noninflamed
patients, IL-10 and Ab-42/40 were associated with delir-
ium. These differences between inflamed and nonin-
flamed ICU patients in delirium-associated biomarkers
suggest that the underlying mechanism governing the
development of delirium in inflamed patients differs
from that in noninflamed patients. Furthermore, we
demonstrated that, in contrast to inflammatory media-
tors, different forms of amyloidb significantly correlate
Table 2 Differences between delirious and nondelirious patients
Delirium (n = 50) Nondelirium (n = 50) Differences P value
Proinflammatory cytokines
TNF-a (pg/ml) 11 [7-14] 8 [5-13] 0.02
IL-1b (pg/ml) 3 [3-6] 3 [3-7] 0.63
IL-6 (pg/ml) 61 [37-113] 37 [23-81] 0.01
IL-8 (pg/ml) 29 [20-39] 17 [9-26] < 0.0001
IL-17 (pg/ml) 3 [3-4] 3 [3-4] 0.17
IL-18 (pg/ml) 99 [74-161] 86 [70-120] 0.11
MIF (pg/ml) 418 [300-724] 257 [157-576] 0.02
Antiinflammatory cytokines
IL-1ra (pg/ml) 36 [17-68] 21 [13-33] 0.001
IL-10 (pg/ml) 29 [16-51] 18 [9-39] 0.01
Chemotactic cytokines
MCP-1 (pg/ml) 372 [248-589] 239 [179-325] < 0.0001
Defensin
HNP (μg/ml) 0.06 [0.03-0.12] 0.06 [0.03-0.10] 0.89
Markers of inflammation
CRP (mg/ml) 56 [35-114] 47 [32-84] 0.11
Procalcitonin (ng/ml) 0.35 [0.17-1.68] 0.14 [0.07-0.36] < 0.0001
Stress-response hormone
Cortisol (μmol/L) 0.51 [0.31-0.97] 0.35 [0.09-0.62] 0.006
Brain-specific proteins
S100-b (pg/ml) 132 [100-294] 135 [90-219] 0.40
Tau (pg/ml) 41 [24-91] 32 [17-56] 0.07
Ratio tau/Ab1-42 1.14 [0.62-2.71] 0.95 [0.47-1.69] 0.10
Ab1-42 (pg/ml) 36 [29-47] 36 [30-41] 0.70
Ab1-40 (pg/ml) 156 [129-225] 146 [113-163] 0.05
Ratio Ab1-42/40 0.23 [0.20-0.27] 0.25 [0.23-0.30] 0.006
AbN-42 (pg/ml) 31 [23-40] 29 [24-36] 0.65
AbN-40 (pg/ml) 222 [167-276] 178 [146-220] 0.02
Ratio Ab N-42/40 0.15 [0.12-0.17] 0.17 [0.14-0.19] 0.04
Ratio Ab1-42/N-42 1.26 [1.03-1.34] 1.29 [1.10-1.40] 0.48
Ratio Ab1-40/N-40 0.78 [0.69-0.85] 0.80 [0.73-0.92] 0.28
Data are expressed as median and IQR. Differences were tested with the Mann-Whitney U test.
aP value < 0.05.
Ab1-42/40, amyloidb1-42 and 1-40; AbN-42/40, amyloidb truncated-42 and 1; CRP, C-reactive protein; HNP, human neutrophil protein-1; IL, interleukin; MCP, monocyte
chemotactic protein 1; MIF, macrophage migration inhibitory factor; NSE, neurospecific enolase; S100-b, S100 calcium-binding protein-b (S100-b);
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with long-term subjective cognitive problems in ICU
patients, illustrating that the underlying mechanism of
delirium is relevant for its long-term cognitive
consequences.
This is the first study investigating plasma amyloidb
(Ab) levels and human Tau in critically ill patients in rela-
tion to the presence of delirium. In view of the reported
increased incidence of dementia after ICU/hospital admis-
sion [16], our findings could provide a possible mechanis-
tic link, because noninflamed delirium is associated with
Ab, but this must be confirmed in a longitudinal study
focusing on these biomarkers combined with more-exten-
sive cognitive testing. Furthermore, Ab is associated with
sustained long-term subjective cognitive dysfunction in
ICU patients. Studies comparing plasma levels of Ab
between Alzheimer (AD) and non-Alzheimer dementia
patients and controls [17,18,32] have yielded conflicting
results with respect to levels of different forms of Ab.
Increased levels of Ab1-42 [17] as well as increased levels of
Ab1-40 [18] were found in dementia patients [32]. In addi-
tion, increased levels of the Tau/Ab1-42 ratio have been
found in cerebrospinal fluid (CSF) of patients with cerebral
amyloid deposition [33], but this has not yet been investi-
gated in plasma. In the present study, the difference in
levels of total Tau and the Tau/Ab1-42 ratio between non-
inflamed delirious patients and noninflamed nondelirious
patients approached statistical significance. It is known
that plasma levels of Ab are age dependent [34]; however,
this could not have confounded our results because no dif-
ferences in age existed between delirious and nondelirious
Table 3 Differences between delirium and nondelirium patients in inflamed and noninflamed patients
Inflamed (n = 46) Noninflamed patients (n = 54)
Delirium (n = 26) Nondelirium (n = 20) P value Delirium (n = 24) Nondelirium (n = 30) P value
Proinflammatory cytokines
TNF-a (pg/ml) 13 [10-16] 11 [5-18] 0.17 8 [5-13] 7 [5-11] 0.18
IL-1b (pg/ml) 3 [3-6] 4 [3-17] 0.67 3 [3-6] 3 [3-6] 0.69
IL-6 (pg/ml) 73 [38-143] 41 [21-90] 0.09 50 [29-90] 34 [22-64] 0.047a
IL-8 (pg/ml) 31 [24-44] 17 [9-26] < 0.001a 20 [12-32] 14 [9-22] 0.001a
IL-17 (pg/ml) 4 [3-7] 3 [3-6] 0.22 3 [3-4] 3 [3-3] 0.63
IL-18 (pg/ml) 136 [88-187] 84 [65-132] 0.03a 82 [66-141] 88 [72-120] 0.54
MIF (pg/ml) 438 [294-796] 257 [157-576] 0.13 334 [214-561] 249 [179-702] 0.08
Antiinflammatory cytokines
IL-1ra (pg/ml) 48 [27-74] 32 [18-47] 0.04a 24 [17-51] 16 [11-25] 0.02a
IL-10 (pg/ml) 23 [13-47] 13 [5-35] 0.08 28 [12-44] 22 [9-46] 0.03a
Chemotactic cytokines
MCP-1 (pg/ml) 516 [295-822] 251 [199-339] 0.001a 268 [192-398] 233 [175-306] 0.15
Defensin
HNP (μg/ml) 0.06 [0.03-0.13] 0.07 [0.03-0.09] 0.60 0.06 [0.04-0.10] 0.04 [0.03-0.10] 0.51
Markers of inflammation
CRP (mg/ml) 84 [56-190] 84 [43-140] 0.40 42 [29-65] 41 [27-64] 0.44
Procalcitonin (ng/ml) 1.0 [0.23-2.0] 0.28 [0.10-0.64] 0.003a 0.22 [0.11-0.55] 0.12 [0.06-0.18] 0.01a
Stress-response hormone
Cortisol (μmol/L) 0.59 [0.34-0.98] 0.48 [0.18-0.61] 0.06 0.46 [0.23-0.72] 0.30 [0.06-0.66] 0.06
Brain-specific proteins
S100-b (pg/ml) 172 [113-409] 134 [88-163] 0.07 128 [87-210] 136 [92-247] 0.60
Tau (pg/ml) 42 [26-131] 43 [24-75] 0.56 40 [21-78] 27 [17-46] 0.08
Ratio tau/Ab1-42 1.03 [0.62-3.45] 1.12 [0.40-2.21] 0.68 1.17 [0.60-2.52] 0.90 [0.48-1.26] 0.07
Ab1-42 (pg/ml) 41 [31-52] 38 [31-42] 0.36 34 [26-43] 36 [30-42] 0.55
Ab1-40 (pg/ml) 158 [132-229] 155 [137-178] 0.55 148 [109-223] 129 [106-158] 0.08
Ratio Ab1-42/40 0.23 [0.20-0.28] 0.24 [0.22-0.26] 0.72 0.22 [0.19-0.26] 0.26 [0.23-0.33] 0.001a
AbN-42 (pg/ml) 31 [26-43] 29 [24-39] 0.57 28 [20-37] 28 [24-35] 0.79
AbN-40 (pg/ml) 200 [167-283] 184 [147-229] 0.24 225 [168-273] 178 [145-220] 0.04a
Ratio Ab N-42/40 0.16 [0.13-0.18] 0.18 [0.12-0.19] 0.47 0.13 [0.10-0.17] 0.16 [0.14-0.20] 0.02a
Ratio Ab1-42/N-42 1.28 [1.00-1.39] 1.31 [1.18-1.48] 0.26 1.24 [1.04-1.33] 1.23 [1.05-1.39] 0.90
Ratio Ab1-40/N-40 0.82 [0.74-0.89] 0.89 [0.73-0.96] 0.27 0.72 [0.65-0.84] 0.76 [0.70-0.87] 0.35
Data are expressed as median and IQR. Differences were tested with the Mann-Whitney U test.
aP value < 0.05.
van den Boogaard et al. Critical Care 2011, 15:R297
http://ccforum.com/content/15/6/R297
Page 6 of 9
patients in our study. Additionally, the patients investi-
gated in this study were not recognized with a history of
cognitive impairment by patients’ medical history and
information from their relatives, which could explain dif-
ferential Ab levels. The lower Ab1-42/40 ratio, probably due
to an increase of Ab1-40 at a constant Ab1-42 level, in com-
bination with a significant correlation with long-term cog-
nitive failure on several domains of the CFQ are in
accordance with findings that elevated levels of Ab1-40
increase the risk of developing dementia [16,18]. Impor-
tantly, this finding of early lower Ab1-42/40 ratio and ratio
Ab1-40/N-40 in delirious patients without signs of serious
previous cognitive impairment makes it tempting to spec-
ulate that this represents the first sign of an imbalance in
the Ab metabolism. To our knowledge, these early find-
ings of imbalance in Ab metabolism have not been
reported. Our findings might therefore shed new light on
the important question whether delirium plays a causative
role in the development of dementia in later life, or if
delirium is the first sign of dementia. Because deposition
of Ab in the brain is generally considered to be a long-
term process, and samples in our study were drawn
shortly after the onset of delirium, it is more plausible that
delirium may be the first sign of an early dementia pro-
cess. However, a cause-effect relation cannot be deter-
mined in a cross-sectional observational study like ours.
This hypothesis of early imbalance in Ab metabolism in
delirious patients must be confirmed in future studies.
Previously, it was demonstrated that delirium is asso-
ciated with elevated levels of IL-6, IL-8, and S100-b in
non-ICU patients [9,10] and with IL-6 and S100-b in
ICU patients with sepsis [13]. IL-8 levels were not mea-
sured in these sepsis patients. We showed, by using a
multivariate logistic regression analysis, that levels of IL-
8 in inflamed patients were associated with delirium,
but IL-6 was not. A possible reason for this discrepancy
might be that we determined biomarkers directly after
the first positive delirium screening, whereas it has been
shown that the highest levels of IL-6 occur in the later
phase of delirium [10].
Several limitations of our study should be addressed.
First, we used the CAM-ICU to diagnose delirium in
ICU patients instead of the gold standard: the DSM-IV
criteria [35]. It is recognized that it is not feasible to use
this gold standard in ICU patients, and therefore the
CAM-ICU is an accepted alternative to diagnose delir-
ium in the ICU. The CAM-ICU has the highest sensitiv-
ity and specificity rate of all delirium-assessment tools
[36,37] and is well implemented in the daily practice of
our nurses with a high interrater reliability [26]. In addi-
tion, to strengthen the delirium diagnosis, all medical
and nurse files of the patients were analyzed, and
patients were not included when in doubt of the delir-
ium diagnosis.
Second, we did not use a validated cognitive-assess-
ment tool such as the informant questionnaire on cogni-
tive decline short form (IQCODE-sf), which is a
surrogate evaluation to determine whether the patient
had serious cognitive impairment before ICU admission.
Instead of this, we used information from medical
records and the next of kin of the patients to identify
whether the patient had a history of cognitive impair-
ment. In case of any reference to or sign of cognitive
impairment, patients were not included in our study.
Furthermore, as a measure of patients’ cognitive func-
tion 18 months after ICU discharge, we used the vali-
dated CFQ, which is a self-evaluated questionnaire to
detect cognitive-based failures and not dementia and is
also not a specific psychometric test, which may result
in more-objective data. Although this can be considered
a limitation of our study, our findings are the results of
patient’s own perception of cognitive functioning and
are therefore informative and relevant.
Third, in this study, we measured biomarkers only at
one point in time. In a longitudinal biomarker study [9],
a difference in cytokine levels before and during delir-
ium was found. In the absence of biomarker data in cri-
tically ill patients with delirium, we chose to perform an
exploratory study to investigate which biomarkers were
most strongly associated with delirium immediately after
the onset of delirium. This was an exploratory hypoth-
esis-generating study, of which the results may facilitate
hypotheses for future research.
Fourth, potential covariates must be considered as a
potential limitation of the study, in contrast to a rando-
mized trial in which possible covariates are likely to be
equally divided between the groups. Although baseline
patient characteristics were comparable between the
delirium and nondelirium groups, unbalanced influence
of covariates cannot be ruled out in such an observa-
tional study as we performed.
Last, we measured levels of brain biomarkers in per-
ipheral blood and not directly in material derived from
the brain or cerebrospinal fluid. It is recognized that
levels of Ab1-42 in cerebrospinal fluid of AD patients are
decreased [38], but studies on plasma Ab forms have
yielded ambiguous results [18,39-43]. A large prospec-
tive study showed that increased plasma levels of Ab1-40
increased the risk for dementia, especially when the con-
centration of Ab1-42 was increased [18]. This results in a
decrease of ratio Ab1-42/40 [40]. A combination of differ-
ent brain-specific proteins, such as a combination of Ab
with Tau concentrations in CSF, improves discrimina-
tion between AD patients and controls [44]. Although it
has been recommended to determine these biomarkers
in CSF rather than in plasma [45], our results are in
accordance with these findings. Interestingly, levels of
Tau, ratio Tau/Ab1-42, and Ab1-40 were increased in
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inflamed delirious and nondelirious patients and in
delirious noninflamed patients, but appear to be lower
in nondelirious noninflamed patients. It can be argued
that a blood-barrier change during systemic inflamma-
tion may play a role. This may also suggest that deter-
mining neuronal biomarkers in plasma can be used
instead of only CSF samples. Obviously, CSF samples
are not routinely obtained in our ICU patients. To our
knowledge, a study investigating the correlation between
CSF and plasma levels of Ab has yet to be performed.
Conclusions
In inflamed patients, the proinflammatory cytokine IL-8
was independently associated with delirium, whereas in
noninflamed patients, the ratio Ab1-42/40 and IL-10 were
independently associated with delirium, as determined by
multivariate regression analyses. This suggests that the
underlying mechanism governing the development of
delirium in inflamed patients differs from that in nonin-
flamed patients. These findings illustrate the relevance of
distinguishing between inflamed and noninflamed when
investigating biomarkers in delirious patients. Finally, ele-
vated levels of amyloid-b correlated with long-term cog-
nitive impairment. These findings are in line with the
notion that delirium in noninflamed ICU patients may
represent the first sign of a (subclinical) dementia pro-
cess. Future research into the relation of delirium, amy-
loid forms, and long-term cognitive function should
include more-extensive tests of cognitive function.
Key messages
• Two different pathways exist in delirious inflamed
and noninflamed ICU patients
• Delirium in inflamed patients is independently
associated with the proinflammatory cytokine IL-8,
and in noninflamed patients, delirium is indepen-
dently associated with the antiinflammatory cytokine
IL-10 and the ratio amyloidb-42/40.
• These increased amyloid-b concentrations, but not
increased cytokine concentrations correlate with
long-term cognitive failure.
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